Summary of Kimball Electronics Q4 2026 Earnings Call

1Key Financial Results and Metrics

Net Sales: $372 million in Q4, a 2% decline year-over-year but a 5% increase sequentially.

Gross Margin: Improved to 8.9%, up 90 basis points from Q4 FY 2025.

Adjusted Operating Income: $18.1 million (4.9% of net sales), down from $19.6 million (5.2% of net sales) in the prior year.

Net Income: $8.5 million ($0.35 per diluted share); adjusted result showed a loss of $163,000 (-$0.01 per diluted share) due to tax impacts.

Cash Flow: Generated $42.4 million from operations, marking the 10th consecutive quarter of positive cash flow.

Debt: Reduced to $116.6 million, the lowest level in over 4 years.

Capital Expenditures: $8.5 million in Q4; total for FY 2026 was $51.7 million.

2Strategic Updates and Business Highlights

Medical Segment: Continued strong performance, with Q4 sales of $109 million (29% of total sales), showing a 1% year-over-year increase. The segment is expected to drive future growth, representing over one-third of total sales in FY 2027.

Acquisition of Helvoet Polymer Technologies: Closed on July 1, 2026. Expected to contribute approximately $60 million in revenue for FY 2027. Integration efforts are progressing well, with a focus on unlocking top-line synergies.

New Facility in Indianapolis: Construction is underway, with production expected to begin by the end of calendar year 2026. Initial production will be a transfer from the existing facility, limiting immediate incremental growth.

3Forward Guidance and Outlook

FY 2027 Sales Projection: Expected to be between $1.535 billion and $1.56 billion, representing a 7% to 9% increase compared to FY 2026.

Organic Growth: Anticipated at 3% to 5%, with Medical expected to grow in the high single to low double-digit range.

Adjusted Operating Income: Estimated to be between 4.4% and 4.7% of net sales.

Capital Expenditures: Projected to be $50 million to $60 million for FY 2027.

4Bad News, Challenges, or Points of Concern

Automotive Segment: Sales declined 3% year-over-year in Q4, with a full-year decline of 7%. The segment is expected to be flat in FY 2027, primarily due to lower demand for electric vehicles (EVs) in North America.

Tax Rate Increase: Effective tax rate for Q4 was 67.8%, significantly higher than the previous year's 48.3%, due to resolution of long-standing tax matters.

Inventory Management: Anticipated pressure on working capital in FY 2027 due to supply chain disruptions and increased customer inventory demands.

5Notable Q&A Insights

Medical Segment Growth Drivers: Growth is expected across various product categories, including surgical devices and drug delivery. However, the ramp-up of the new facility in Indianapolis may not contribute significantly to growth in FY 2027.

Helvoet Integration: No major surprises post-acquisition; customer retention appears strong, and integration is progressing as planned. Currency fluctuations may impact revenue from Helvoet.

Capital Allocation Strategy: The company aims to maintain a leverage ratio between 1.5x and 2x EBITDA, balancing investments in organic growth, share repurchases, and potential inorganic opportunities. Overall, Kimball Electronics reported a solid finish to FY 2026, with a focus on strategic growth in the medical sector and successful integration of Helvoet, despite challenges in the automotive segment and increased tax burdens. The outlook for FY 2027 is cautiously optimistic, with expectations for organic growth and continued investment in capabilities.